Panobinostat

Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of various cancers. It is a hydroxamic acid[2] and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).[3] On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma,[4][5] and on 28 August 2015 it was approved by the European Medicines Agency for the same use.[6] ... [wikipedia]